Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
22.32
+0.12 (0.54%)
At close: Jul 17, 2026, 4:00 PM EDT
21.89
-0.43 (-1.93%)
After-hours: Jul 17, 2026, 5:44 PM EDT
Immunome Revenue
Immunome had revenue of $4.01M in the twelve months ending March 31, 2026, down -63.29% year-over-year. In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$4.01M
Revenue Growth
-63.29%
P/S Ratio
629.58
Revenue / Employee
$19,490
Employees
206
Market Cap
2.53B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 535.08M |
| Vericel | 292.09M |
| Agios Pharmaceuticals | 66.05M |
| Nurix Therapeutics | 36.77M |
| uniQure | 18.09M |
IMNM News
- 9 days ago - Immunome’s NDA for varegacestat in desmoid tumors accepted by FDA - TheFly
- 9 days ago - Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors - Business Wire
- 10 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Immunome announces first patient dosed in Phase 1 trial of IM-1617 - TheFly
- 5 weeks ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - Business Wire
- 5 weeks ago - Immunome Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Immunome announces Ringside trial met primary, secondary endpoints - TheFly